Researchers question efficacy of approved koala chlamydia vaccine

Queensland scientists say a published study contains a mistake that over-inflates the effectiveness of a vaccine approved to fight chlamydia in endangered koalas.

Researchers question efficacy of approved koala chlamydia vaccine
Photo: The Guardian

Queensland researchers say a published study contains a 'silly mistake' that over-inflates the efficacy of a vaccine approved to treat koalas. The veterinary medicines regulator is standing by its decision to approve the vaccine.

The vaccine, a single-dose protein-based product, was approved by the Australian Pesticides and Veterinary Medicines Authority in September 2025. Professor Keith Chappell, a molecular virologist at the University of Queensland, has questioned its efficacy. He took issue with a 2024 paper published in npj Vaccines which claimed the vaccine significantly lowered disease incidence and resulted in a 64% reduction in chlamydia deaths over a 10-year period.

Chlamydia is the most significant disease affecting koalas, with prevalence as high as two in three in some populations. The bacterium Chlamydia pecorum is commonly spread via mating or close contact. Infected females can rapidly become infertile, and heavily diseased animals can become emaciated.

Antibiotic treatments are often unsuccessful because they can kill the gut microbes koalas need to digest toxic eucalypt leaves. This can lead to weight loss, diarrhoea, or fatal microbial imbalances. Additionally, some chlamydia strains have developed antibiotic resistance.

Researchers at the Queensland University of Technology are developing a different two-dose vaccine. To address the difficulty of catching wild koalas for a second shot, they have developed a biodegradable, non-toxic implant that delivers the second dose over a few weeks. This implant is currently being trialled in wild koalas but has not yet been approved by the APVMA.

Key facts

  • A single-dose protein-based chlamydia vaccine was approved by the APVMA in September 2025.
  • Professor Keith Chappell questioned a 2024 study claiming the vaccine reduced chlamydia deaths by 64% over 10 years.
  • Chlamydia prevalence is as high as two in three in some koala populations.

Three perspectives

Neutral

The veterinary medicines regulator is maintaining its approval of a chlamydia vaccine despite researcher claims of an error in efficacy data.

Positive

Researchers at QUT have developed a biodegradable implant to deliver a second vaccine dose to wild koalas.

Negative

Chlamydia is a major threat to endangered koalas, causing infertility and potentially fatal digestive issues.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition